The global vaccine alliance Gavi says it will buy 500,000 doses of vaccine against mpox to fight outbreaks of the disease in African countries.

The global vaccine group Gavi will buy 500,000 doses of Bavarian Nordic's mpox vaccine, its first purchase of the shot to help battle an outbreak in parts of Africa, the group said on Wednesday. In 2024,

Gavi, the global vaccine group, announced it will purchase 500,000 doses of Bavarian Nordic’s mpox vaccine. This marks Gavi’s first acquisition of the vaccine to aid in combating an outbreak in parts of Africa.

Gavi, the Vaccine Alliance, will purchase 500,000 doses of MVA-BN, the Bavarian Nordic Mpox vaccine, as part of an international effort to combat the outbreak of Mpox in certain parts of Africa.

The global vaccine group Gavi has ordered 500,000 mpox vaccine doses from the German-Danish company Bavarian Nordic. The UN Children's Fund is to deliver these to affected countries in Africa later this year,

Gavi, the Vaccine Alliance and the U.K. government ordered a combined 650,000 doses of Bavarian Nordic’s Jynneos mpox vaccine just days after the Danish drugmaker announced it would focus its resources to produce as many as 2 million doses by the end of 2024.

Gavi has committed to purchasing 500,000 doses of Bavarian Nordic's mpox vaccine to address the ongoing outbreak in Africa, particularly in the Democratic Republic of Congo. The initiative involves a $50 million spend,

More than 26,500 mpox cases and 724 deaths have been reported in 15 African countries since the beginning of this year, according to the Africa Centres for Disease Control and Prevention (Africa CDC),

Gavi, the Vaccine Alliance, and Bavarian Nordic today announced an advanced purchase agreement to secure 500,000 doses of Jynneos mpox vaccine for African countries, which will be delivered this year.